Skip to content

Identification of biomarkers and pathogenesis for early gastric cancer based on plasma metabolomics and machine learning

Identification of biomarkers and pathogenesis for early gastric cancer based on plasma metabolomics and machine learning

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500109654
Enrollment
Unknown
Registered
2025-09-23
Start date
2023-09-05
Completion date
Unknown
Last updated
2025-09-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Early gastric cancer

Interventions

Gold Standard:Gastroscopy + pathology
Index test:Plasma biomarker early gastric cancer diagnosis model

Sponsors

Peking University First Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Stomach cancer group: 1. Gastroscopy at the Endoscopy Center of Peking University First Hospital; 2. Complete clinical data; 3. Signed informed consent; 4. Age >= 18 and = 18 and <= 80 years; 5. No known malignant tumors outside of the stomach.

Exclusion criteria

Exclusion criteria: Gastric cancer group: 1. Age 80 years; 2. Known concurrent or past malignant tumors at other sites besides gastric cancer; 3. Underwent treatments such as endoscopy, surgery, or chemotherapy/radiotherapy; 4. Refusal to participate in the study or incomplete clinical data; 5. Concurrent metabolic diseases or hematologic disorders; 6. Concurrent underlying diseases such as cardiovascular, liver, or kidney diseases; 7. Women in lactation or pregnancy; 8. Significant stress response occurred within 2 weeks before blood sampling; 9. Any acute disease symptoms within 2 weeks before blood sampling; 10. Special medications (antibiotics, hormones, non-steroidal anti-inflammatory drugs, etc.) taken within 2 weeks before blood sampling. Healthy control group: 1. Age 80 years; 2. Known concurrent or past malignant tumors at other sites besides gastric cancer; 3. Underwent treatments such as endoscopy, surgery, or chemotherapy/radiotherapy; 4. Refusal to participate in the study or incomplete clinical data; 5. Concurrent metabolic diseases or hematologic disorders; 6. Concurrent underlying diseases such as cardiovascular, liver, or kidney diseases; 7. Women in lactation or pregnancy; 8. Significant stress response occurred within 2 weeks before blood sampling; 9; Any acute disease symptoms within 2 weeks before blood sampling; 10. Special medications (antibiotics, hormones, non-steroidal anti-inflammatory drugs, etc.) taken within 2 weeks before blood sampling.

Design outcomes

Primary

MeasureTime frame
General data;Information on endoscopy;Pathological findings;Performance evaluation indicators of diagnostic models;

Countries

China

Contacts

Public ContactFeng Wang

Peking University First Hospital

bjmuwangfeng@126.com+86 10 83572437

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026